cathepsin S inhibitors (GlaxoSmithKline)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug Namecathepsin S inhibitors (GlaxoSmithKline)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCathepsin S inhibitors
TargetsCathepsin S
Therapy Area/IndicationsAutoimmune DiseasesArteriosclerosisMultiple Sclerosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Inc
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesArteriosclerosisMultiple Sclerosis +[5] 

Other Information

ATC CodeN/A
Related LinksN/A